PA
MCK icon

PharVision Advisers’s McKesson MCK Stock Holding History

PharVision Advisers’s Portfolio MCK Stock Details MCK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-260
Closed -$213K – 423
2025
Q4 		$213K Sell
260
-7
-3% -$5.71K 0.11% 509
2025
Q3 		$206K Sell
267
-86
-24% -$60.6K 0.12% 492
2025
Q2 		$259K Buy
353
+32
+10% +$22.6K 0.37% 123
2025
Q1 		$216K Buy
+321
New +$198K 0.3% 180

Other funds holding MCK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's MCK Position: Q1 2026 in Review

PharVision Advisers sold out of McKesson (MCK) in Q1 2026, closing a stake of 260 shares — an estimated $213K sold.

PharVision Advisers first reported a position in MCK in Q1 2025 and held it in 4 quarters. The position peaked at $259K in Q2 2025. 2,033 funds tracked by Wall St. Rank hold MCK as of Q1 2026.

  • PharVision Advisers reported no remaining McKesson position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 260 McKesson shares in Q1 2026, an estimated $213K.
  • PharVision Advisers first reported a position in McKesson in Q1 2025 and held it in 4 quarters.
  • PharVision Advisers's McKesson position peaked at $259K in Q2 2025.
  • 2,033 funds tracked by Wall St. Rank held McKesson as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.